Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price hit a new 52-week low during mid-day trading on Monday . The stock traded as low as C$0.06 and last traded at C$0.06, with a volume of 117018 shares. The stock had previously closed at C$0.07.
Hemostemix Stock Performance
The firm has a fifty day simple moving average of C$0.07 and a 200-day simple moving average of C$0.08. The firm has a market cap of C$11.31 million, a P/E ratio of -2.22 and a beta of 0.59. The company has a debt-to-equity ratio of -72.45, a current ratio of 0.49 and a quick ratio of 0.48.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.
Further Reading
- Five stocks we like better than Hemostemix
- D-Wave Earnings Looked Weak, But Investors May Be Missing This
- Nebius Upside Expands as AI Feedback Loop Intensifies
- Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell
- Plug Power Flips The Switch On Profitability
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
